Saxenda Side Effects: FDA Label, Higher-Dose Liraglutide for Weight Management
Saxenda is the higher-dose, weight-management formulation of liraglutide approved by the FDA for chronic weight management in adults with obesity, and in adolescents aged 12 to 17 with obesity. The same molecule at a lower dose is sold as Victoza for type 2 diabetes. According to the FDA prescribing information, the most common adverse reactions are gastrointestinal, the label carries a boxed warning for thyroid C-cell tumours, and the label includes a specific warning to monitor for suicidal thoughts or behaviour.
Saxenda (Liraglutide (weight-management dose)) is an FDA-approved once-daily glp-1 receptor agonist for weight management. The most common adverse reactions per the FDA label are gastrointestinal. The label carries a boxed warning for thyroid C-cell tumours and lists pancreatitis, kidney injury, gallbladder disease, and hypoglycaemia with insulin or sulfonylureas as serious risks. This page summarises label and EMA information; it is not medical advice.
Key Takeaways
- Saxenda is the weight-management dose of liraglutide (3 mg daily), the same molecule as Victoza at a higher dose.
- FDA boxed warning for thyroid C-cell tumours. Contraindicated in personal or family history of MTC or MEN2.
- Most common adverse reactions per the FDA label: nausea, hypoglycaemia (in T2DM patients), diarrhoea, constipation, vomiting, headache, decreased appetite, dyspepsia, fatigue, dizziness, abdominal pain, and increased lipase.
- Labelled serious risks include acute pancreatitis, gallbladder disease, acute kidney injury, suicidal behaviour and ideation (monitor mood), increased heart rate, hypersensitivity, and hypoglycaemia with insulin or sulfonylureas.
- Approved for adolescents aged 12 to 17 with obesity, which is a distinguishing feature compared with most GLP-1 weight-management drugs.
What is Saxenda, and what is it approved for?
Saxenda is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with a BMI ≥30 (or ≥27 with a weight-related comorbidity), and in adolescents 12 and older with obesity. The SCALE trial programme supported the approval.
| Property | Detail |
|---|---|
| Generic name | Liraglutide (3 mg daily) |
| Brand | Saxenda (Novo Nordisk) |
| Drug class | GLP-1 receptor agonist |
| Route | Subcutaneous injection, once daily |
| Approved indications (FDA) | Chronic weight management in adults with BMI ≥30 (or ≥27 with comorbidity), and adolescents 12+ with obesity |
| Boxed warning | Thyroid C-cell tumours |
| Notable label warning | Monitor for suicidal behaviour and ideation |
| Common adverse reactions per FDA label | Nausea, diarrhoea, constipation, vomiting, headache, decreased appetite, dyspepsia, fatigue, dizziness, abdominal pain |
How does Saxenda work?
Saxenda contains liraglutide, the same molecule as Victoza, but is titrated to a higher daily dose (3 mg) for weight management. Per the FDA label, liraglutide stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on appetite centres in the central nervous system to reduce hunger and food intake.
What side effects has Saxenda been linked to in trials?
The following summary is drawn from the FDA prescribing information and EMA product information. It is for general information and does not replace advice from your prescriber.
| Category | Listed reactions / risks | Source |
|---|---|---|
| Boxed warning | Thyroid C-cell tumours (animal data) | FDA label |
| Pancreatitis | Severe, persistent abdominal pain; advise discontinuation and urgent assessment | FDA label |
| Acute kidney injury | Usually secondary to dehydration from GI side effects | FDA label |
| Severe hypoglycaemia | Risk increases with insulin or insulin secretagogues; dose reduction usually required | FDA label |
| Gallbladder disease | Cholelithiasis and cholecystitis reported | FDA label |
| Common GI reactions | Nausea, diarrhoea, vomiting, constipation, abdominal pain | FDA label, EMA EPAR |
| Hypersensitivity | Rash, urticaria, angioedema, anaphylaxis | FDA label |
| Aspiration risk during anaesthesia | Delayed gastric emptying may retain food in the stomach during sedation | ASA / multi-society guidance |
Taking Saxenda alongside other medications?
Allmeds scans the widest interaction database for free, so you can talk to your doctor with a clear picture.
Common Questions About Saxenda
Both contain liraglutide. Saxenda is FDA-approved for chronic weight management at 3 mg daily; Victoza is approved for type 2 diabetes at lower doses up to 1.8 mg daily. The active molecule is identical. The Saxenda label includes a specific warning to monitor for suicidal behaviour and ideation, in addition to the boxed warning for thyroid C-cell tumours shared with Victoza.
Both are FDA-approved for chronic weight management, but they contain different GLP-1 receptor agonists. Saxenda is liraglutide given once daily; Wegovy is semaglutide given once weekly. Head-to-head trial data (STEP 8) reported greater weight loss with semaglutide vs liraglutide at the studied doses. Direct comparisons should be discussed with your clinician.
Per the FDA label, common adverse reactions include nausea, diarrhoea, constipation, vomiting, headache, decreased appetite, dyspepsia, fatigue, dizziness, and abdominal pain. They are typically dose-related and most prominent during dose titration.
Yes. The FDA prescribing information advises monitoring patients for suicidal thoughts or behaviour, with consideration of discontinuation if symptoms develop. This is in addition to the boxed warning for thyroid C-cell tumours.
The FDA label approves Saxenda for adolescents aged 12 to 17 with obesity. Any paediatric use should be initiated and managed by a qualified specialist, and the same major warnings apply.
References
- U.S. Food & Drug Administration. Saxenda (liraglutide) prescribing information. Source.
- European Medicines Agency. Saxenda EPAR product information. Source.
- Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE). N Engl J Med. 2015;373:11-22. Source.
- Rubino DM et al. Effect of weekly semaglutide vs daily liraglutide on body weight (STEP 8). JAMA. 2022;327:138-150. Source.
- Therapeutic Goods Administration (Australia). Australian Register of Therapeutic Goods (ARTG). Source.